BioMarin Pharmaceutical upgraded by Raymond James with a new price target
Raymond James upgraded BioMarin Pharmaceutical from Outperform to Strong Buy and set a new price target of $109.00
Analyst Ratings
Delayed 3mReal-time analyst upgrades, downgrades, and price targets.
Signed out · 3-min delay · Sign up for real-time
- Longbow initiated coverage on Amrize
Longbow initiated coverage of Amrize with a rating of Buy
- Barclays initiated coverage on York Space Systems with a new price target
Barclays initiated coverage of York Space Systems with a rating of Equal Weight and set a new price target of $11.00
- Barclays resumed coverage on Vertical Aerospace Group with a new price target
Barclays resumed coverage of Vertical Aerospace Group with a rating of Equal Weight and set a new price target of $1.00
- BMO Capital Markets initiated coverage on Synchrony Financial with a new price target
BMO Capital Markets initiated coverage of Synchrony Financial with a rating of Market Perform and set a new price target of $81.00
- Barclays initiated coverage on RTX with a new price target
Barclays initiated coverage of RTX with a rating of Overweight and set a new price target of $223.00
- Barclays initiated coverage on Rocket Lab USA with a new price target
Barclays initiated coverage of Rocket Lab USA with a rating of Overweight and set a new price target of $85.00
- Raymond James initiated coverage on Quince Therapeutics with a new price target
Raymond James initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $72.00
- Barclays initiated coverage on Planet Labs with a new price target
Barclays initiated coverage of Planet Labs with a rating of Equal Weight and set a new price target of $17.00
- BofA Securities initiated coverage on Penguin Solutions with a new price target
BofA Securities initiated coverage of Penguin Solutions with a rating of Buy and set a new price target of $100.00
- Raymond James initiated coverage on Palisade Bio with a new price target
Raymond James initiated coverage of Palisade Bio with a rating of Outperform and set a new price target of $6.00
- Barclays initiated coverage on Palantir Technologies with a new price target
Barclays initiated coverage of Palantir Technologies with a rating of Overweight and set a new price target of $265.00
- Cantor Fitzgerald initiated coverage on Ovid Therapeutics
Cantor Fitzgerald initiated coverage of Ovid Therapeutics with a rating of Overweight
- Barclays initiated coverage on Northrop Grumman with a new price target
Barclays initiated coverage of Northrop Grumman with a rating of Underweight and set a new price target of $419.00
- Raymond James initiated coverage on Nektar Therapeutics
Raymond James initiated coverage of Nektar Therapeutics with a rating of Mkt Perform
- Piper Sandler initiated coverage on Mid Penn Bancorp with a new price target
Piper Sandler initiated coverage of Mid Penn Bancorp with a rating of Overweight and set a new price target of $42.00
- Barclays initiated coverage on Lockheed Martin with a new price target
Barclays initiated coverage of Lockheed Martin with a rating of Equal Weight and set a new price target of $554.00
- Canaccord Genuity initiated coverage on LB Pharmaceuticals with a new price target
Canaccord Genuity initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $65.00
- Raymond James initiated coverage on Kymera Therapeutics with a new price target
Raymond James initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $140.00
- Barclays initiated coverage on Kratos Defense and Security with a new price target
Barclays initiated coverage of Kratos Defense and Security with a rating of Overweight and set a new price target of $90.00